Clinical Trial Update: Safety and Tolerability of Vortioxetine (LuAA21004) - Open Label Extension Study [Phase 3]

View source ↗

Summary

This open-label Phase 3 extension study assessed the safety and tolerability of vortioxetine (LuAA21004) in adults with major depressive disorder. The trial is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Vortioxetine (vortioxetine)

Snippet

Sponsor: Takeda | Conditions: Depressive Disorder, Major | Phase 3 | Status: COMPLETED | Results posted: 2014-05-28